Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
February 27 2024 - 4:05PM
Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a
clinical-stage precision oncology focused on the discovery and
development of next-generation small molecule kinase inhibitors,
today announced that management will participate in a panel
discussion at TD Cowen’s 44th Annual Health Care Conference in
Boston, MA, on Tuesday, March 5, 2024, at 12:50 p.m. ET.
The panel will be webcast live and can be accessed
by visiting the investor relations section of the Company’s website
at https://ir.enliventherapeutics.com/. The webcast will be
archived for a period of 30 days following the conclusion of the
live event.
About Enliven TherapeuticsEnliven
Therapeutics is a clinical-stage biopharmaceutical company focused
on the discovery and development of small molecule inhibitors to
help patients with cancer not only live longer, but better. Enliven
aims to address existing and emerging unmet needs with a precision
oncology approach that improves survival and enhances overall
patient well-being. Enliven’s discovery process combines deep
insights in clinically validated biological targets and
differentiated chemistry to design potentially first-in-class or
best-in-class therapies. Enliven is based in Boulder, Colorado.
Contact:Investorsir@enliventherapeutics.com
Mediamedia@enliventherapeutics.com
Enliven Therapeutics (NASDAQ:ELVN)
Historical Stock Chart
From Apr 2024 to May 2024
Enliven Therapeutics (NASDAQ:ELVN)
Historical Stock Chart
From May 2023 to May 2024